Clinical & Experimental Allergy· 2026Q2
PROTEGO Study Protocol: A Cluster Randomised Crossover Trial of Vernix Caseosa Retention for Primary Prevention of Atopic Dermatitis
- 0citations
- Q2SCImago
- 2026year
Short summary
The PROTEGO study protocol outlines a cluster-randomised crossover trial to test if retaining vernix caseosa (the cheesy coating on newborns) prevents atopic dermatitis (eczema) in infants.
AI-generated from the title and abstract; the full text is not read.
Key points
- The PROTEGO study is a cluster-randomised crossover trial.
- It aims to prevent atopic dermatitis (eczema) in infants.
- The intervention involves retaining vernix caseosa (newborn skin coating).
- 1383 mother-infant dyads will be enrolled and followed for 12 months.
AI-generated from the title and abstract; the full text is not read.
Abstract
Summary PROTEGO is a Chilean cluster‐randomised crossover trial of vernix caseosa retention to prevent atopic dermatitis. 1383 mother‐infant dyads will be enrolled and followed for atopic dermatitis until 12 months.
The authors' abstract, as published at the source. Clinical & Experimental Allergy, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Dermatology
DermatologyMedicine